The effect of adding rituximab to high dose chemotherapy

U Vitolo; A Chiappella; G Rossi; E Angelucci; M Liberati; E Liberati

doi:10.4081/hmr.v2i7.426

Abstracts

8 June 2009

Vol. 2 No. 7 (2006)

https://doi.org/10.4081/hmr.v2i7.426

The effect of adding rituximab to high dose chemotherapy

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

PDF

244

Views

424

Downloads

Authors

U Vitolo

support@pagepress.org

A Chiappella

G Rossi

E Angelucci

M Liberati

E Liberati

High-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) has been proved to be an effective salvage treatment in chemo-sensitive relapsed patients for both aggressive and indolent lymphomas. Since that, many investigators have extended this approach as part of the initial therapy of patients with aggressive lymphomas, especially those considered at poor prognosis, with conflicting results in randomized studies. Indeed a recent meta-analyses of up to 11 randomized trials in aggressive lymphomas, showed a similar OS in patients receiving first-line HDC + ASCT or standard chemotherapy.